Liquidia (NASDAQ:LQDA) Price Target Raised to $44.00 at Wells Fargo & Company

Liquidia (NASDAQ:LQDA) had its target price increased by Wells Fargo & Company from $31.00 to $44.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

LQDA has been the topic of a number of other reports. Jefferies Financial Group lifted their target price on Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, January 13th. HC Wainwright increased their price target on shares of Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research report on Sunday, January 18th. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Liquidia Stock Performance

Shares of LQDA stock traded up $1.51 during trading on Friday, hitting $36.03. The company’s stock had a trading volume of 2,306,542 shares, compared to its average volume of 1,900,515. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19. The company has a market cap of $3.13 billion, a PE ratio of -43.41, a P/E/G ratio of 0.60 and a beta of 0.52. The business has a fifty day moving average of $37.10 and a 200-day moving average of $30.89. Liquidia has a 52 week low of $11.26 and a 52 week high of $46.67.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Liquidia had a negative return on equity of 237.79% and a negative net margin of 43.53%.The business had revenue of $92.02 million for the quarter. The business’s revenue for the quarter was up 3072.4% compared to the same quarter last year. As a group, research analysts anticipate that Liquidia will post -1.51 earnings per share for the current year.

Insider Activity

In related news, insider Scott Moomaw sold 20,533 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $768,550.19. Following the sale, the insider directly owned 154,514 shares in the company, valued at approximately $5,783,459.02. The trade was a 11.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 66,610 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $2,493,212.30. Following the sale, the chief executive officer directly owned 1,037,528 shares in the company, valued at approximately $38,834,673.04. This trade represents a 6.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 212,534 shares of company stock worth $7,964,719. 26.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Liquidia in the fourth quarter worth about $25,000. Covestor Ltd lifted its stake in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares in the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in Liquidia in the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC bought a new position in Liquidia in the 3rd quarter worth approximately $34,000. Finally, NewEdge Advisors LLC purchased a new position in Liquidia in the 2nd quarter valued at approximately $25,000. Institutional investors own 64.54% of the company’s stock.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).